The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells

Vascular disrupting agents (VDAs) represent a promising class of anti-cancer drugs for solid tumor treatment. Here, we aim to better understand the mechanisms underlying tumor reccurrence and treatment resistance following the administration of a VDA, combretastatin A-4 phosphate (CA4P). Firstly, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Dey, Sanchareeka, Kumari, Sharda, Kalainayakan, Sarada Preeta, Campbell, James, Ghosh, Poorva, Zhou, Heling, FitzGerald, Keely E., Li, Maoping, Mason, Ralph P., Zhang, Li, Liu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790523/
https://www.ncbi.nlm.nih.gov/pubmed/29423106
http://dx.doi.org/10.18632/oncotarget.23734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790523/
https://www.ncbi.nlm.nih.gov/pubmed/29423106
http://dx.doi.org/10.18632/oncotarget.23734

Ejemplares similares